Ascendis Pharma A/S expected to post a loss of €1.47 a share - Earnings Preview

Ascendis Pharma A/S

29/04/2025 21:35

Ascendis Pharma A/S ASND.OQ, ASND.O is expected to show a fall in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

The Hellerup Denmark-based   company is expected to report a 1.3% decrease in revenue to €94.644 million from €95.89 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of €1.47 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 16.3% in the last three months. ​

Wall Street's median 12-month price target for Ascendis Pharma A/S is $200.00​, above​ its last closing price of $164.88. ​​​

Previous quarterly performance (using preferred earnings measure in euros). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.84
-0.96
-0.64
Beat
33.2
Sep. 30 2024
-1.76
-1.74
-1.72
Beat
1.2
Jun. 30 2024
-1.34
-1.38
-1.91
Missed
-38.1​
Mar. 31 2024
-1.46
-1.50
-2.30
Missed
-53.1
​​Dec. 31 2023
-1.98
-2.03
-1.54
Beat
24
Sep. 30 2023
-2.32
-2.38
-2.88
Missed
-21.1​
Jun. 30 2023
-2.57
-2.59
-2.16
Beat
16.6
Mar. 31 2023
-2.65
-2.66
-1.98
Beat
25.6

This summary was machine generated April 29 at 20:35 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)